Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BIO-TECHNE (TECH) EBITDA Margin: 2009-2025

Historic EBITDA Margin for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to 11.75%.

  • BIO-TECHNE's EBITDA Margin fell 616.00% to 11.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.06%, marking a year-over-year decrease of 834.00%. This contributed to the annual value of 7.53% for FY2025, which is 592.00% down from last year.
  • According to the latest figures from Q3 2025, BIO-TECHNE's EBITDA Margin is 11.75%, which was up 728.73% from 1.42% recorded in Q2 2025.
  • In the past 5 years, BIO-TECHNE's EBITDA Margin registered a high of 3,647.25% during Q3 2022, and its lowest value of 1.42% during Q2 2025.
  • Over the past 3 years, BIO-TECHNE's median EBITDA Margin value was 12.33% (recorded in 2024), while the average stood at 13.50%.
  • As far as peak fluctuations go, BIO-TECHNE's EBITDA Margin surged by 362,293bps in 2022, and later slumped by 363,315bps in 2023.
  • Over the past 5 years, BIO-TECHNE's EBITDA Margin (Quarterly) stood at 31.53% in 2021, then plummeted by 698bps to 24.56% in 2022, then plummeted by 921bps to 15.34% in 2023, then crashed by 1,220bps to 3.14% in 2024, then slumped by 616bps to 11.75% in 2025.
  • Its last three reported values are 11.75% in Q3 2025, 1.42% for Q2 2025, and 8.28% during Q1 2025.